Nexstim
Consolidating both shares and strategyNexstim
Rights issue 178% oversubscribedNexstim
Subscription rights issue of €6.6m at €0.03 per shareNexstim
A positive start to the 2020-24 strategyNexstim
Promising results for severe depression pilot studyNexstim
Planning the next phase of growthNexstim
€0.9m prototype research project signedNexstim
Pilot studies lift off in depression and painNexstim
Mapping out the 2020-24 corporate strategyNexstim
€2.3m rights issue is 273% subscribed